ArticleDiscover oncology2026
Antineoplastic effect of piperine compared with doxorubicin via suppressing γ-secretase/notch pathway in breast cancer cells.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast carcinoma is the most prevalent and lethal malignancy affecting females, and it always presents an essential healthcare problem. Doxorubicin (DOX) is a common chemotherapy utilized in treating breast carcinoma, but it also has dangerous side effects. Hence, searching for potent and safe anticancer compounds is urgent. An alkaloid, piperine, mostly found in pepper species, is a naturally occurring substance with anticancer properties. This work aims to assess the anticancer impact of piperine on breast carcinoma cells by potentially inhibiting the γ-secretase/Notch pathway, and to compare its impacts with those of DOX. The anti-proliferative effects of piperine and DOX were evaluated on various human breast carcinoma cell lines (MCF-7, T47D, and MDA-MB-231). Additionally, a flow cytometric analysis was carried out to identify the cell cycle arrest. Moreover, the protein expression levels of Notch-1, γ-secretase components, NICD, c-myc, p21, Bax, and Bcl-2 were assessed. The results demonstrated that among the tested cell lines, MDA-MB-231 cells exhibited the highest sensitivity to piperine treatment, with the lowest IC
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.